Filing Details
- Accession Number:
- 0000899243-19-007350
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-03-12 19:15:03
- Reporting Period:
- 2019-03-11
- Accepted Time:
- 2019-03-12 19:15:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1346302 | Xeris Pharmaceuticals Inc | XERS | Pharmaceutical Preparations (2834) | 203352427 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1531178 | R Paul Edick | C/O Xeris Pharmaceuticals, Inc. 180 N. Lasalle Street, Suite 1600 Chicago IL 60601 | See Remarks | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-03-11 | 30,000 | $9.12 | 155,000 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 13,430 | Indirect | By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 |
Footnotes
- The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.98 to $9.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Billionaire Hedge Funds
